For patients with HER2-positive early breast cancer who had a residual invasive disease, von Minckwitz et al. demonstrated that the risk of recurrence or death was 50% lower with adjuvant TDM-1 than with trastuzumab alone [24]. This evidence concerns the gene ERBB2 and breast cancer.